Advances in Relapsed/Refractory Multiple Myeloma: Insights From Dr. Rahul Banerjee

2 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Explore the latest advancements in relapsed/refractory multiple myeloma research here: https://oncdata.com/rrmm-task-force-additional-advances

In this edition of Additional Advances, Dr. Rahul Banerjee, Assistant Professor of Medicine at Fred Hutchinson Cancer Center, shares insights into the evolving landscape of relapsed/refractory multiple myeloma (RRMM). As co-chair of i3 Health’s Multiple Myeloma Task Force, Dr. Banerjee discusses recent progress in CAR T-cell therapy, including its growing role as a second-line treatment, and the emergence of bispecific antibodies as a promising alternative for patients without access to CAR T therapy.

Dr. Banerjee also highlights efforts to address healthcare disparities, reduce driving restrictions post–CAR T-cell therapy, and make advanced therapies more accessible for patients in rural and underserved areas.

Stay informed about the latest innovations in RRMM treatment and strategies to improve patient care and equity in oncology.

#MultipleMyeloma #CAR_TTherapy #BispecificAntibodies #OncologyResearch #CancerTreatment #RahulBanerjee #BloodCancer #RelapsedRefractoryMyeloma #HealthcareEquity #OncologyCare
Category
Oncology
Be the first to comment

Up Next